How Little Moderna Made Big Waves In Trial Diversity
Executive Summary
Early on, the company committed to transparency while making sure its Phase III vaccine study enrolled a population reflective of the US as a whole. Moderna talks to Scrip about the experience.
You may also be interested in...
COVID-19 Vaccine Trial Efficiencies, Leadership Alignment: What Can Be Carried Forward
Operational actions, organizational responses and clinical development model improvements led to a 26-month acceleration, on average, in a set of COVID-19 vaccine pivotal trials versus similarly sized pre-pandemic studies, with the database lock and analysis stage delivering dramatic gains, a study by IQVIA Institute indicates. Can these benefits be recapitulated across the portfolio in the post-pandemic era?
How To Improve Diversity And Inclusion: Five Companies Share Best Practices
Company strategies at improving diversity, equity and inclusion both within their organizations and in the clinical trials they conduct have differed, but building trust is a common theme.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.